Study Name:
A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.
Study Dates:
October 8, 2025 - December 7, 2029
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Industry
Sponsors:
Merck Sharp & Dohme LLC
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT07190248
